Source: Eur Respir Rev, 30 (159) 200340; 10.1183/16000617.0340-2020
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Madelon C. Vonk, Ulrich A. Walker, Elizabeth R. Volkmann, Michael Kreuter, Sindhu R. Johnson, Yannick Allanore. Natural variability in the disease course of SSc-ILD: implications for treatment. Eur Respir Rev, 30 (159) 200340; 10.1183/16000617.0340-2020

Member's Comments

No comment yet.

Related content which might interest you: Complexity in chronic asthma and COPD: implications for risk assessment, disease progression and control Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium Year: 2008 Does anti-acid treatment influence disease progression in SSc-ILD ? data from the German SSc-network Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new? Year: 2019 Key recommendations for monitoring disease course of IPF Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: evidence based guidelines and recommendations for clinical management - Results of the joint ATS/ERS/JRS taskforce Year: 2009 COPD as a lung disease with heterogeneous systemic inflammatory consequences: clinical impact Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011 Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment Source: Annual Congress 2009 - Sarcoidosis in review Year: 2009 The natural history of untreated NTM lung disease: a global perspective Source: International Congress 2017 – Clinical impact of nontuberculous mycobacterial (NTM) disease Year: 2017 Assessing the effectiveness of pirfenidone in changing the natural course of idiopathic pulmonary fibrosis: the data from European IPF Registry (eurIPFreg). Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Does the HLA-DRB1-genotype influence the course of disease in Danish sarcoidosis patients? Source: Annual Congress 2013 –Sarcoidosis Year: 2013 Initial clinical phenotype of COPD: Correlation with the natuaral history of the disease Source: Annual Congress 2011 - COPD management Year: 2011 Clinical course of childhood asthma: a role of disease severity Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children Year: 2008 Immunodeficiencies in adulthood: lung disease manifestations and treatment options Source: International Congress 2019 – PG6 Immunodeficiencies in lung diseases Year: 2019 Serum exosomes from IPF patients display a fibrotic miRNA profile that correlates to clinical measures of disease severity Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Assessing the effect of medical therapy in COPD: from pathophysiology and biomarkers to clinical practice Source: Annual Congress 2009 - PG15 The complexity of COPD: assessment and advanced therapies Year: 2009 The disease model: implications for clinical practice Source: Eur Respir J, 51 (4) 1800188; 10.1183/13993003.00188-2018 Year: 2018 Monitoring of pulmonary function in Pompe disease: a muscle disease with new therapeutic perspectives Source: Eur Respir J 2005; 26: 984-985 Year: 2005 Mast cells in lung disease: clinical implications Source: International Congress 2019 – It takes two to tango: translating scientific findings into clinical applications Year: 2019 PROFILEing idiopathic pulmonary fibrosis: rethinking biomarker discovery Source: Eur Respir Rev 2013; 22: 148-152 Year: 2013 Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021 Interstitial lung disease: new challenges and evolving phenotypes Source: Eur Respir Rev 2009; 19: 91-93 Year: 2010